Cwm LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX)

CWM LLC boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 136.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,617 shares of the biopharmaceutical company's stock after purchasing an additional 11,883 shares during the period. CWM LLC's holdings in Royalty Pharma were worth $642,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Louisbourg Investments Inc. bought a new stake in Royalty Pharma in the first quarter worth $28,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of Royalty Pharma by 76.4% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 414 shares during the last quarter. Allworth Financial LP raised its stake in shares of Royalty Pharma by 41.6% during the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 452 shares during the last quarter. National Bank of Canada FI raised its stake in shares of Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 371 shares during the last quarter. Finally, Westpac Banking Corp bought a new position in shares of Royalty Pharma during the fourth quarter valued at about $53,000. 54.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup upped their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Morgan Stanley set a $54.00 price objective on shares of Royalty Pharma and gave the company an "overweight" rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Royalty Pharma presently has an average rating of "Buy" and an average price target of $49.00.

Royalty Pharma Trading Up 0.2%

RPRX stock traded up $0.08 during trading on Friday, reaching $36.67. The company had a trading volume of 1,927,054 shares, compared to its average volume of 2,931,223. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $36.89. The company has a market cap of $20.62 billion, a P/E ratio of 19.82, a PEG ratio of 2.44 and a beta of 0.50. The business has a 50 day moving average of $34.80 and a 200 day moving average of $33.07. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. The company had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. As a group, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date is Friday, August 15th. Royalty Pharma's payout ratio is currently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.